PrEP Implementation and Monitoring

Therapeutic Adherence and Dosage Regimens

The preventive success of pre-exposure prophylaxis depends critically on strict adherence to prescribed administration guidelines.

Sustained treatment adherence is essential for maintaining continuous protective concentrations of the medication in the body’s mucous membranes.

There are two main clinically approved dosing regimens.

The first is the continuous daily regimen, recommended for all populations and characterized by providing constant protection once adequate tissue saturation levels are reached.

The second regimen is on-demand or event-based administration, structured by taking two tablets between two and twenty-four hours before intimate contact, followed by a dose twenty-four hours later and another forty-eight hours later.

While the daily regimen requires establishing a routine, the on-demand regimen demands rigorous advance planning on the part of the user.

In both cases, unplanned interruptions or missed doses dramatically reduce drug concentration in vulnerable tissues, creating windows of biological susceptibility during which the virus can evade the protective barrier and infect immune cells.

Clinical Follow-ups and Periodic Testing

The medical follow-up protocol for users of pre-exposure prophylaxis requires systematic monitoring scheduled every three months.

The primary objective of these periodic consultations is to reconfirm the patient’s seronegative status through state-of-the-art laboratory testing.

This constant verification is essential to prevent the inadvertent administration of prophylactic therapy in the presence of a recent seroconversion, a situation that would lead to the development of antiretroviral-resistant viral strains.

Additionally, clinical follow-up includes regular assessment of renal function by measuring serum creatinine levels and the glomerular filtration rate, as certain components of the medication can cause changes in kidney tissue.

Furthermore, each quarterly visit provides an opportunity for comprehensive screening for other urogenital and rectal bacterial infections, enabling timely diagnosis and immediate treatment of asymptomatic conditions.

This continuous monitoring regimen ensures that long-term use of the medication maintains a high safety profile and maximum preventive effic